Mechanisms of Inactivation of PTCH1 Gene in Nevoid Basal Cell Carcinoma Syndrome: Modification of the Two-Hit Hypothesis

Purpose: PTCH1 has been identified as the gene responsible for nevoid basal cell carcinoma syndrome (NBCCS). Keratocystic odontogenic tumors (KCOT) are aggressive jaw lesions that may occur in isolation or in association with NBCCS. The aim of this study was to investigate the genetic and/or epigenetic mechanisms of inactivation of the PTCH1 gene in patients with NBCCS and related sporadic KCOTs. Experimental Design: Loss of heterozygosity was analyzed in 44 patients (15 NBCCS-related and 29 sporadic KCOTs), all of whom were previously analyzed for PTCH1 mutations. Allelic location was established in tumors carrying two coincident mutations. PTCH1 mRNA expression and promoter methylation status were analyzed in a panel of KCOTs to define the possible role of epigenetic effects on PTCH1 inactivation. Results: Although mutations and loss of heterozygosity of PTCH1 were frequently detected in both syndromic and nonsyndromic cases, hypermethylation of the PTCH1 promoter was not identified in the present series. Of all the 44 cases examined, 13 were identified to fit the two-hit model, 14 to conform to a one-hit model, and the remaining 17 cases showing no alteration in PTCH1. The distribution of two-hit, one-hit, and non-hit cases was significantly different between syndrome and nonsyndrome patients (P < 0.02). Conclusions: This study indicates that PTCH1 gene alternation may play a significant role in the pathogenesis of NBCCS and the related sporadic tumors. Not only the standard two-hit model, but also haploinsufficiency or dominant-negative isoforms may be implicated in the inactivation of the PTCH1 gene. Clin Cancer Res; 16(2); 442–50

[1]  T. Li,et al.  Epithelial cell proliferation in odontogenic keratocysts: a comparative immunocytochemical study of Ki67 in simple, recurrent and basal cell naevus syndrome (BCNS)-associated lesions. , 1995, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[2]  H. Phillip Koeffler,et al.  Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer , 2007, Breast Cancer Research and Treatment.

[3]  Z. Bian,et al.  Germline Mutations of the PTCH Gene in Families with Odontogenic Keratocysts and Nevoid Basal Cell Carcinoma Syndrome , 2006, Tumor Biology.

[4]  J. Louhelainen,et al.  Dinucleotide repeat polymorphism within the tumor suppressor gene PTCH at 9q22 , 1998, Clinical genetics.

[5]  R. Gorlin.  Nevoid basal cell carcinoma (Gorlin) syndrome , 2004, Genetics in Medicine.

[6]  D. Evans,et al.  Age related shift in the mutation spectra of germline and somatic NF2 mutations: hypothetical role of DNA repair mechanisms , 2005, Journal of Medical Genetics.

[7]  M. Rosemann,et al.  Unbalanced overexpression of the mutant allele in murine Patched mutants. , 2002, Carcinogenesis.

[8]  M. Karagas,et al.  Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin. , 2006, The Journal of investigative dermatology.

[9]  A. Knudson.  Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Michael Dean,et al.  Mutations of the Human Homolog of Drosophila patched in the Nevoid Basal Cell Carcinoma Syndrome , 1996, Cell.

[11]  R. Gorlin,et al.  A two-hit model for developmental defects in Gorlin syndrome , 1996, Nature Genetics.

[12]  V. P. Collins,et al.  Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumours , 1997, Oncogene.

[13]  L. Kindblom,et al.  Deregulation of the hedgehog signalling pathway: a possible role for the PTCH and SUFU genes in human rhabdomyoma and rhabdomyosarcoma development , 2006, The Journal of pathology.

[14]  R. Gomez,et al.  PTCH Gene Mutations in Odontogenic Keratocysts , 2000, Journal of dental research.

[15]  Lei Zhou,et al.  Distinct consequences of sterol sensor mutations in Drosophila and mouse patched homologs. , 2002, Developmental biology.

[16]  S. Pan,et al.  PTCH1 mutations in odontogenic keratocysts: are they related to epithelial cell proliferation? , 2009, Oral oncology.

[17]  H. Kumamoto,et al.  PTC gene mutations and expression of SHH, PTC, SMO, and GLI-1 in odontogenic keratocysts. , 2004, International journal of oral and maxillofacial surgery.

[18]  Li-li Xu,et al.  [PTCH2 gene alterations in keratocystic odontogenic tumors associated with nevoid basal cell carcinoma syndrome]. , 2008, Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences.

[19]  R. L. Johnson,et al.  In vivo functions of the patched protein: requirement of the C terminus for target gene inactivation but not Hedgehog sequestration. , 2000, Molecular cell.

[20]  R. Browne,et al.  The odontogenic keratocyst and its occurrence in the nevoid basal cell carcinoma syndrome. , 1987, Oral surgery, oral medicine, and oral pathology.

[21]  T-J. Li,et al.  PTCH1 and SMO Gene Alterations in Keratocystic Odontogenic Tumors , 2008, Journal of dental research.

[22]  A. Goldstein,et al.  Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. , 1997, American journal of medical genetics.

[23]  A. Berns,et al.  Haplo-insufficiency? Let me count the ways. , 2001, Genes & development.

[24]  T. Curran,et al.  The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. , 2000, Cancer research.

[25]  Joel I. Pritchard,et al.  Methylation of PTCH1, the Patched-1 gene, in a panel of primary medulloblastomas. , 2008, Cancer genetics and cytogenetics.

[26]  R. Browne.  The odontogenic keratocyst. Histological features and their correlation with clinical behaviour , 1971, British Dental Journal.

[27]  S. Levanat,et al.  The Patched gene is epigenetically regulated in ovarian dermoids and fibromas, but not in basocellular carcinomas. , 2007, International journal of molecular medicine.

[28]  E. Haan,et al.  Further localization of the gene for nevoid basal cell carcinoma syndrome (NBCCS) in 15 Australasian families: linkage and loss of heterozygosity. , 1993, American journal of human genetics.

[29]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[30]  R. Fodde,et al.  CANCER BIOLOGY: Enhanced: A Matter of Dosage , 2002 .

[31]  T-J. Li,et al.  PTCH Mutations in Sporadic and Gorlin-syndrome-related Odontogenic Keratocysts , 2006, Journal of dental research.

[32]  T-J. Li,et al.  PTCH germline mutations in Chinese nevoid basal cell carcinoma syndrome patients. , 2008, Oral diseases.

[33]  H. Wichterle,et al.  Identification of a small molecule inhibitor of the hedgehog signaling pathway: Effects on basal cell carcinoma-like lesions , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  R. Toftgård.  Hedgehog signalling in cancer , 2000, Cellular and Molecular Life Sciences CMLS.

[35]  M. Scott,et al.  Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice , 2000, Genes, chromosomes & cancer.

[36]  B. Wainwright,et al.  Functional analysis in Drosophila indicates that the NBCCS/PTCH1 mutation G509V results in activation of smoothened through a dominant‐negative mechanism , 2004, Developmental dynamics : an official publication of the American Association of Anatomists.

[37]  M. Greene,et al.  Developmental defects in gorlin syndrome related to a putative tumor suppressor gene on chromosome 9 , 1992, Cell.